PRESS RELEASES OF INDUSTRY-SPONSORED CLINICAL TRIALS IN ONCOLOGY: CHARACTERISTICS, TIMING AND FINANCIAL IMPACT.

ALLIANCE AGAINST CANCER 18-20 SETTEMBRE-VERONA 10TH ANNUAL MEETING: NEW TECHNOLOGIES AND STRATEGIES TO FIGHT CANCER

TRASTUZUMAB DERUXTECAN (T-DXd)+PERTUZUMAB (P) vs TAXANE+TRASTUZUMAB+PERTUZUMAB (THP) FOR FIRST-LINE (1L) TREATMENT OF PATIENTS (pts) WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) ADVANCED/METASTATIC BREAST CANCER (a/mBC): INTERIM RESULTS FROM DESTINY-BREAST09